Bundle of 5x Retatrutide 30mg Single Vials.
*Bundled vials do not always come labeled. Subject to availability*
Product Details
Triple Incretin Receptor Agonist | GLP-1 + GIP + Glucagon for Advanced Fat Loss & Metabolic Optimization
Overview:
Retatrutide is a next-generation triple incretin agonist, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and Glucagon receptors simultaneously. This unique triple-action mechanism offers a powerful blend of appetite suppression, fat oxidation, and energy regulation, positioning Retatrutide at the forefront of advanced weight management and metabolic enhancement therapies.
This product is supplied as a lyophilized powder and requires reconstitution before use.
*Bundled vials do not always come labeled. Subject to availability*
*Bundled Products are excluded from coupons and BOGO offers*
Why Choose Retatrutide 30mg (5-Vials Bundle)?
Retatrutide delivers a more comprehensive metabolic approach by activating three complementary hormonal pathways rather than one or two.
Its compounded effects on appetite control, lipid metabolism, and energy expenditure make it an ideal option for high-response fat-loss protocols and advanced body recomposition strategies, particularly at higher-capacity kit strengths.
Key Benefits
• Promotes deep, sustained fat loss through increased metabolic rate
• Strong appetite and craving suppression
• Enhances insulin sensitivity and glycemic control
• Supports lipid metabolism and energy balance
• Once-weekly subcutaneous dosing for convenience
Reconstitution Instructions
• Reconstitute using Bacteriostatic Water (BAC)
• Example: Add 2mL of BAC to a 5mg vial for a 2.5mg/mL solution
• Gently swirl (do not shake) until dissolved completely
• Store reconstituted Retatrutide in the refrigerator (2–8°C)
• Use within 28 days of reconstitution
Typical Dosing Guidelines
• Initial dose: start low (e.g., 0.25–0.5mg weekly)
• Therapeutic range: 1–5mg+ weekly, titrated based on tolerance and goal
• Administer via subcutaneous injection (abdomen, thigh, or upper arm)
• Duration: 12–24 weeks typical for significant body composition changes
Monitoring & Considerations:
• Common side effects: Nausea, fullness, slowed digestion, mild fatigue (usually temporary)
• Monitor: Blood glucose, hydration, GI tolerance, and lipid markers
• Contraindications: History of medullary thyroid carcinoma (MTC) or MEN2 syndromes
Note
Reviews
There are no reviews yet.